Investor Insights from CEOs & CFOs | Financial Results & Presentations | seat11a

Carl Zeiss Meditec AG Deep Dive: Q&A

Financial and Strategic Outlook: Insights from Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG

US Equipment Sales and Market Dynamics

Why Were US Equipment Sales, Especially in Microsurgery, Weak in Q3?

Market Context: Weakness in microsurgery sales was driven by the late product cycle of older equipment and the launch of the new KINEVO 900 S neurosurgical platform in October 2024. Transition periods between product generations are typically slower.

Financing Challenges: Private equity-backed clinics in the US, a significant customer segment, delayed investments due to high interest rates and expectations of an economic turnaround.

Recovery Outlook: With the launch of KINEVO 900 S and early stabilization in order entries at the start of FY25, ZEISS anticipates returning to growth in the US market by 2025.

Cost-Cutting Plans and Margin Impact

Can You Summarize Your Cost-Cutting Plans and Their Impact on Margin Goals?

Background: R&D expenses peaked at 17% of sales in FY22 due to investments in digitalization, AI, and cloud-based infrastructure. These investments have built a robust ecosystem of integrated solutions.

Optimization Strategy:

Adjusted R&D prioritization by focusing on high-impact products.

Implemented more responsive planning tools to align R&D investments with market conditions.

Reduced or slowed down investments in areas with longer monetization timelines or less immediate commercial potential.

Impact on Margins: These adjustments aim to improve productivity and preserve innovation while maintaining ZEISS’s leadership as the most R&D-intensive company in the ophthalmology industry.

Bridging 2024 Guidance to 2025 Profitability

How Do You Bridge 2024 Guidance to the Profitability Step-Up Expected in 2025E?

Drivers of Recovery:

-Full-year contribution from the DORC acquisition.

-Recovery in the Chinese market from inventory destocking.

-Continued cost efficiencies in R&D and sales operations.

-Stabilized equipment sales and new product launches, including the KINEVO 900 S and QUATERA 700.

Macro Conditions: While macroeconomic uncertainty persists, ZEISS expects a gradual improvement in consumer sentiment and demand across key markets.

Profitability Targets: The company targets an EBIT margin recovery of 16-20%, depending on macroeconomic developments.

R&D Strategy Under Cost Reduction Plan

What Is Your R&D Strategy Under the Cost-Reduction Plan, and Where Will Savings Occur?

Digital Investments: With foundational investments in cloud infrastructure complete, future spending will focus on developing applications and monetizable use cases.

Integration of DORC: Streamlined development plans across cataract and retinal product lines, leveraging synergies from the DORC acquisition.

Portfolio Focus: Narrowed the portfolio of premium IOLs to concentrate on high-potential products with the best commercial return.

Conclusion

With a clear focus on profitability, innovation, and market recovery, Carl Zeiss Meditec AG is well-positioned for long-term growth. The company’s strategic initiatives, including the launch of advanced products like the KINEVO 900 S and optimized R&D investments, highlight its resilience and ability to adapt to evolving market dynamics.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, discusses the company’s strategic initiatives and recent acquisitions, focusing on the US market rollout of QUATERA 700, the impact of the DORC acquisition, and feedback on the integrated ZEISS cataract workflow. This comprehensive analysis underscores ZEISS’s efforts to expand its market potential and strengthen its leadership in ophthalmology and vitreoretinal surgery.

Strategic Initiatives and Rollouts

Status of QUATERA 700 Rollout and Its Impact on Cataract Surgical Plans

QUATERA 700 Introduction: Launched in 2022, the QUATERA 700 fills a critical gap in ZEISS’s portfolio as an advanced phacoemulsification (phaco) system for cataract surgery.

Challenges: Initial sales have been modest due to delays in obtaining approvals for complementary intraocular lenses (IOLs), particularly premium lenses essential for competitive bundled offerings.

Future Plans: ZEISS is heavily investing in R&D to enhance the system’s features, accessories, and integration capabilities. The company targets midterm market share gains by leveraging QUATERA’s capabilities alongside its broader cataract product suite.

Impact of the DORC Acquisition on the Vitreoretinal Market

Strategic Fit: The acquisition of Dutch retinal surgery specialist DORC in 2023 has positioned ZEISS as a global leader in vitreoretinal solutions.

Opportunities in the US: DORC’s established customer base provides ZEISS with an entry point for promoting its IOLs and other complementary products. This synergy is expected to strengthen ZEISS’s position in the US market.

China Expansion: With its extensive presence and long-standing relationships in China, ZEISS is accelerating DORC’s market penetration, leveraging local expertise and distributor networks.

Future Integration: The acquisition enables ZEISS to create a comprehensive retinal workflow, combining diagnostic imaging, surgical microscopes, and consumables for improved clinical outcomes.

Feedback on ZEISS Cataract Workflow

Customer Feedback: The integrated ZEISS cataract workflow has received highly positive feedback for its ability to streamline surgical preparation, reduce complications, and enhance patient outcomes.

Efficiency Gains: Studies indicate a 40-50% reduction in surgery preparation and setup time, alongside measurable time savings during procedures due to reduced complications.

Market Positioning: ZEISS’s fully connected ecosystem of devices and software is becoming the industry standard, setting it apart from competitors offering standalone solutions.

Market Potential and Synergies

Cross-Selling Opportunities: DORC’s retinal customer base offers significant cross-selling potential for ZEISS’s cataract solutions, including IOLs and surgical microscopes.

Conclusion

Carl Zeiss Meditec AG’s strategic rollouts, including QUATERA 700 and the integration of DORC, showcase the company’s commitment to innovation and market expansion. With a strong focus on delivering comprehensive solutions and leveraging synergies across its portfolio, ZEISS is well-positioned to capitalize on the growing demand in the global ophthalmology and vitreoretinal surgery markets.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In-Depth Video Summary for Equity Investors: RENK Group AG Presentation by CEO Susanne Wiegand on Seat11a

In a strategic presentation hosted on Seat11a, Susanne Wiegand, the CEO of RENK Group AG, outlined the company’s vision and robust financial health amidst a dynamic global market. RENK, a leader in propulsion solutions, is segmented into defence and civil sectors, with a strong emphasis on sustainability and technological innovation. This solid financial position provides a stable foundation for potential investors.

Corporate Overview and Strategic Direction

Wiegand introduced RENK, highlighting its dual focus: dominating the tracked military vehicles and surface combatant markets, while advancing the energy transition through high-speed gear technologies. She detailed the company’s revenue streams, noting that 70% of its revenue comes from the defence sector, underscoring RENK’s undisputed leadership in its core markets.

Financial Performance

RENK’s financial strength was a key point, with Wiegand reporting a total order backlog of €4.6 billion, five times the company’s revenues for the last 12 months. This figure showcases the company’s strong market demand and financial stability. The geographic diversification of its end customers across Europe, the Middle East, Africa, APAC, and the Americas mitigates risks related to customer concentration.

Operational Segments and Innovations

The CEO broke down RENK’s operations into three main segments:

1. Vehicle Mobility Solutions (VMS): This segment focuses on transmissions and includes engines, suspensions, and electric drive test systems. It primarily serves the defence industry and is central to RENK’s market leadership.

2. Marine and Industry (M&I): This segment comprises high-speed gears, couplings, and clutches, enhancing RENK’s presence in the naval and industrial sectors.

3. Slide Bearings: RENK specializes in products supporting various industrial applications, reinforcing its market presence.

R&D and Market Strategy

Wiegand stressed the importance of RENK’s self-funded R&D, pivotal in maintaining technological leadership without burdening the company’s capital expenditures. The strategic focus on aftermarket services, which make up 36% of the business, allows RENK to enjoy high margins and maintain strong customer retention.

Future Outlook and Growth Strategies

Looking ahead, Wiegand outlined ambitious plans to scale operations and double revenue in the midterm through strategic acquisitions and enhanced operational efficiency. The recent IPO and listings reflect RENK’s market readiness and investor confidence. Wiegand also touched on strategic acquisitions in the U.S., positioning RENK strongly in the North American markets.

Sustainability and Long-term Vision

Concluding her presentation, the CEO reiterated RENK’s commitment to sustainability, focusing on both environmental impact through its energy sector products and its role in global security. The long lifespan of its defence products and ongoing innovations in gear technology for energy applications position RENK as a key player in both sectors’ future landscapes, aligning with the values of socially responsible investors.

---

Other Videos:

- Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

- Company Presentation: https://seat11a.com/investor-relations-company-presentation/

- Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

- Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

- ESG Presentation: https://seat11a.com/investor-relations-esg/

---

Terms & Conditions

This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on https://www.seat11a.com/legal and https://www.seat11a.com/imprint.

Carl Zeiss Meditec AG Elevator Pitch: Key Takeaways

Carl Zeiss Meditec AG: Market Leadership and Strategic Outlook

Corporate Overview

In this engaging elevator pitch, Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, provides a concise yet comprehensive introduction to the company’s equity story, market leadership, and growth potential. As one of the world’s leading medical technology companies, Carl Zeiss Meditec dominates the fields of ophthalmology and microsurgery, combining innovation with a strong market presence that instils confidence in our investors and stakeholders.

- Revenue: Carl Zeiss Meditec generates €2 billion in annual revenue.

- Ownership: 59% of the company is owned by Carl Zeiss AG, a global optics and imaging powerhouse.

- Business Segments:

 -- Ophthalmology: Dominates with innovative solutions across diagnostics, refractive surgery, cataract surgery, and retinal treatments.

 -- Microsurgery: Focuses on neurosurgery, spinal surgery, ENT, and plastic/reconstructive surgery, with world-leading visualization systems.

 -- Recurring Revenue: Approximately 47% of revenue is recurring, driven by consumables, software, and services, offering stability and margin growth.

Market Leadership and Growth Drivers

Ophthalmology

- Refractive Surgery: ZEISS is a global leader with a 40% market share, offering life-changing solutions like SMILE therapy to treat myopia.

- Cataract Surgery: Continues to expand market share with premium intraocular lenses and surgical workflows.

- Retinal Surgery: Holds a strong #2 position globally, recently enhanced by the DORC acquisition.

Microsurgery

- ZEISS maintains a 60% global market share in neurosurgical and spinal visualization, delivering cutting-edge intraoperative diagnostic solutions.

Geographic Presence and Opportunities

- Asia-Pacific: Represents the largest market, driven by high rates of myopia and ageing populations, particularly in China.

- US and Europe: Continue to offer significant growth opportunities through portfolio expansion and product rollouts.

- Emerging Markets: Heavy investment in India and Southeast Asia positions ZEISS for long-term growth in high-potential regions.

Innovation and R&D

- R&D Leadership: ZEISS leads the industry in R&D investment, focusing on digitalization, AI, and connected workflows.

- Integrated Workflows: The company’s unique approach to combining devices, software, and consumables into unified workflows sets it apart, enhancing clinical outcomes and customer loyalty.

Strategic Outlook for FY 2024/25

- Challenging Macro Environment: Despite headwinds in the consumer and equipment markets, ZEISS is poised for moderate revenue growth and gradual margin recovery.

- Product Launches: New offerings like the KINEVO 900 S and VISUMAX 800 are expected to drive growth in the second half of FY25.

- DORC Integration: The full-year consolidation of the DORC acquisition provides significant opportunities in the retinal surgery market.

Addressing the Myopia Pandemic

ZEISS addresses the growing global prevalence of myopia, which is projected to affect 50% of the world’s population by 2050.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

BRAIN Biotech AG FY 2023/24: Key TakeawaysFinancial Performance Overview

Despite a challenging economic environment, BRAIN Biotech reported an adjusted EBITDA of €-0.4 million, a slight decrease from the previous year’s €+0.4 million. This resilience is a testament to the company’s strength and potential for future growth, especially given the substantial investments in the company’s BioIncubator projects. Schneiders emphasized the company’s strong cash position, stating,

“With a strong focus on the successful execution of strategic initiatives, we have been able to bring our group cash position to a very comfortable level of €27.2 million and to reduce our cost base significantly for the running financial year.”

A significant highlight of the year was the monetization of royalty rights to the investigational compound deucrictibant, resulting in a transaction valued up to €128.88 million. This deal included an immediate upfront payment of €18.41 million, with potential for additional regulatory and sales-related milestones. Schneiders noted,

“Royalty monetization is a very interesting and innovative form of alternative non-dilutive financing for us in an ultra-low BRAIN Biotech share price environment.”

The company has significantly reduced its cost base and positions, improving profitability in the upcoming financial year. Schneiders expressed confidence in the company’s trajectory, stating,

“We have laid excellent foundations for success in the years to come. Hence, we forecast a positive adjusted EBITDA for 2024/25.”

Looking ahead, BRAIN Biotech is focused on accelerating its transformation into a global top-ten player in the industrial enzymes market, with a strong emphasis on the Food, Beverage, and Life Sciences sectors. The company plans to utilize proceeds from recent transactions to fund growth initiatives, including potential mergers and acquisitions, and to repay short-term loans. Schneiders conveyed optimism about the company’s future, highlighting the BioIncubator pipeline’s crystallizing value and the organization’s ongoing structural developments.

In summary, under Michael Schneiders’s financial stewardship, BRAIN Biotech AG has navigated a challenging fiscal year with strategic foresight, maintaining financial stability while investing in future growth. The company’s proactive approach to cost management, innovative financing, and strategic investments position it well for a promising future in the industrial biotechnology sector.

Strategic Initiatives and InvestmentsCost Management and EfficiencyFuture OutlookConclusion

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Introduction to Carl Zeiss Meditec AG by Sebastian Frericks, Head of Investor Relations

Sebastian Frericks, Head of Investor Relations, delivered an engaging and insightful presentation on Carl Zeiss Meditec AG, a globally recognised leader in Ophthalmology and Microsurgery. This presentation comprehensively overviewed the company’s market position, key strategies, and future growth drivers.

The company achieved €2,089 million in revenue in the 2023/24 fiscal year, with a historically solid EBIT margin of 12%. Carl Zeiss Meditec is a market leader with a 40% share in Refractive Surgery and a growing market share in Surgery Anterior (Cataract). Listed on MDAX and TecDAX, Carl Zeiss Meditec is 59% owned by Carl Zeiss AG, a private optics and technology powerhouse.

Key Business Segments

Ophthalmology

- Revenue Contribution: Comprises 77% of total revenue and focuses on diagnosis, treatment, and surgical solutions.

- Key Subsegments:

- Chronic Disease Management

- Refractive Surgery

- Cataract Treatment

- Retinal Treatment

- Market Leadership: Includes a 40% share in Refractive Surgery and a growing share in Anterior Surgery (Cataract).

Microsurgery

- Revenue Contribution: Contributes 23% of revenue, focusing on high-tech surgical visualisation for Neurosurgery, ENT, Plastic Surgery, and Dentistry.

- Market Leadership: ZEISS dominates the microsurgical market with a 60% global share.

Geographic Reach and Structural Tailwinds

Regional Insights:

- The Asia-Pacific region is a key growth driver, accounting for 26% of revenue, with China as the largest single market.

- Other significant regions include the US, Germany, and Southeast Asia.

Structural Growth Drivers:

- Ageing populations lead to increased cataract surgeries.

- Rising myopia prevalence, particularly in Asia, where up to 90% of young people have myopia.

- Growing demand for digitalised workflows and premium surgical solutions.

Innovation and Strategic Investments

R&D Investment: Carl Zeiss Meditec commits 16.7% of revenue to R&D.

Key Innovations:

- VISUMAX®️ 800: A cutting-edge refractive laser surgery system.

- KINEVO®️ 900 S: Neurosurgery platform designed for efficiency and better surgical outcomes.

- Digital Solutions: Investments focus on connectivity and integrated workflows to enhance clinical outcomes and customer loyalty.

Key Growth Drivers

- Expansion in emerging markets, including India and Southeast Asia.

- Increasing demand for premium intraocular lenses (IOLs) for cataract surgeries, forecasted to grow in unit and revenue share.

- Advancements in refractive laser surgery driven by rising global myopia rates.

Future Outlook

FY 2024/25 Goals:

- Moderate revenue growth supported by product launches, including VISUMAX®️ 800 approvals in key markets like the US and China.

Macroeconomic Challenges:

- Includes constrained consumer spending and investment climates.

Profitability Targets:

- Long-term EBITA margin target of 16-20%.

Conclusion

Sebastian Frericks closed the presentation by emphasising Carl Zeiss Meditec’s unique market position, strong brand, and commitment to innovation as key factors driving sustainable growth and customer loyalty.

This strong brand is a testament to the company’s reputation for quality and reliability.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

AIXTRON SE Company Presentation: Key Takeaways

Introduction to AIXTRON by Christian Ludwig, Head of Investor Relations and Corporate Communications

Christian Ludwig, Head of Investor Relations and Corporate Communications at AIXTRON, delivers a concise yet powerful elevator pitch, highlighting the company’s impressive 40-year journey. AIXTRON has established itself as a trusted global technology leader in deposition systems, addressing transformative industries with cutting-edge solutions and a strong legacy of innovation.

Corporate Overview

Founded: 1983, as a university spin-off from RWTH Aachen.

Global Reach: Over 1,100 employees across nine countries, with R&D and production facilities in Germany, the UK, and Italy.

Technology Leadership: More than 3,500 deposition systems sold worldwide, with a proven track record in Power Electronics, Optoelectronics, and Laser applications.

Key Growth Applications

AIXTRON’s product portfolio is tailored for four primary growth applications:

Power Electronics

Silicon Carbide (SiC): Revolutionizing EV main inverters, chargers, and wind power systems.

Gallium Nitride (GaN): Powering fast chargers, motor drives, and AI power delivery solutions.

Optoelectronics

LED Systems: Enabling next-gen industrial displays, automotive lighting, and horticulture.

Micro LEDs and Specialty LEDs: Transforming AR glasses, TVs, and automotive interiors.

Laser Technology

Applications in 3D Sensing, LiDAR, and Optical Data Communication.

Growth Outlook

Recent Growth: Robust revenue growth driven by SiC and GaN applications.

2025 Transition: A flat-to-slight revenue decline is expected due to market adjustments.

Long-Term Potential: Market demand is forecasted to double by 2028/29, driven by electrification, AI, IoT, and sustainable energy trends.

Strategic Achievements and Execution

Portfolio Evolution: Continuous upgrades with the G10 product family ensure market competitiveness.

Market Expansion: Successfully entered the SiC market while maintaining strong shares in GaN and Optoelectronics.

ESG Alignment: High alignment with EU Taxonomy regulations demonstrates a commitment to sustainability.

Key Megatrends and Market Drivers

Electrification and energy efficiency.

AI, digitization, and communication technologies.

Internet of Things (IoT) and intelligent devices.

Transition to advanced materials in power and display applications.

Investor Appeal

Christian Ludwig concludes by emphasizing AIXTRON’s ability to outpace market growth through superior technology and alignment with structural megatrends. He invites investors to explore the company’s unique equity story, driven by long-term profitability and sustainability.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A

Q&A with Carl Zeiss Meditec AG’s Head of Investor Relations, Sebastian Frericks

China Market and Recovery Expectations

Update on China’s Refractive Market and Recovery Expectations for 2024

Market Context: Carl Zeiss Meditec remains the leading player in China’s refractive laser surgery market, having experienced over a decade of growth at a CAGR exceeding 20%. However, since China’s reopening post-COVID in 2023, the market has faced challenges, including a shift to lower-cost procedures and reduced patient traffic. Utilization rates for installed laser systems declined in the high single digits during late 2024.

Seasonality: The refractive business is seasonal, with peaks during Lunar New Year (January-February) and the summer vacation period (July-August).

Outlook: A turnaround is expected in the second half of fiscal year 2024/25 with the rollout of the VisuMax 800, an advanced refractive laser platform offering faster and more precise procedures. Despite the current cautious macroeconomic environment, strong indications of clinic demand point to potential growth in late 2025.

Trends in Downtrading from SMILE to LASIK in China

Observations on Shifts in Procedure Preferences:

- Market Shift: The weak consumer environment has shifted preferences from the minimally invasive SMILE therapy to less expensive LASIK procedures. Previously, SMILE accounted for 80% of treatments, but this mix has shifted to 65-70% SMILE and 30-35% LASIK.

- Revenue Impact: This mix change has significantly impacted revenue, as SMILE procedures generate higher margins.

- Strategic Response: The upcoming VisuMax 800 platform aims to improve the mix by introducing higher-value consumables and addressing the changing consumer landscape.

Impact of Volume-Based Procurement (VBP) on IOL Volumes

How Has VBP Affected the Intraocular Lens (IOL) Business?

VBP Rollout: The Chinese government’s volume-based procurement (VBP) system has lowered intraocular lens prices, resulting in significant price reductions across the value chain. While this has pressured margins, volume increases have partially offset the revenue impact.

Long-Term Opportunity: With an ageing population and high cataract prevalence, the Chinese market for IOLs has substantial untapped potential. The company expects affordability improvements to drive long-term growth.

APAC (Excluding China) Performance

Market Dynamics in APAC

Regional Highlights: Southeast Asia, including Vietnam, Indonesia, Malaysia, and Singapore, shows strong growth in refractive laser and cataract procedures.

India: Economic growth and wealth creation are expected to significantly expand the middle-class market, increasing demand for elective procedures. The company has been directly present in India for over 30 years and is optimistic about its long-term potential.

Conclusion

Sebastian Frericks highlights Carl Zeiss Meditec AG’s resilience amid market challenges, emphasizing the company’s strategic positioning, leadership in innovation, and long-term growth potential across global markets. Despite short-term headwinds in China, the company remains optimistic about recovery and expansion opportunities driven by advanced technologies and strong market presence.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A

Q&A with Carl Zeiss Meditec AG’s Head of Investor Relations, Sebastian Frericks

US Refractive Market Performance and Competitive Landscape

Has refractive competition increased in 2024, particularly from J&J’s ELITA or Staar Surgical?

- J&J’s ELITA: While J&J has entered some markets with their ELITA system, it has yet to gain significant traction in major markets like the US and China due to regulatory hurdles and limited product features. Notably, the system lacks approval for its SILK procedure, which is positioned as a competitor to ZEISS’s SMILE therapy.

- Staar Surgical: The overlap between ZEISS’s laser-based refractive solutions and Staar Surgical’s ICL (implantable collamer lens) business is minimal. ICLs cater to niche cases, such as high myopia corrections, where laser-based therapies have limitations. ZEISS maintains a competitive edge in broader applications due to its extensive track record and safety profile, with over 10 million SMILE procedures performed globally.

- Strategic Positioning: ZEISS is poised to strengthen its competitive edge with the upcoming rollout of the VisuMax 800, a more advanced platform designed to enhance procedure speed, precision, and patient outcomes.

How is your US refractive business performing amid reports of soft demand?

- Market Trends: The US market has faced a decline in refractive procedure volumes in 2024 due to high interest rates and reduced consumer spending capacity. Unlike Europe or Asia, a large proportion (approximately 65%) of US refractive procedures are financed, making the market particularly sensitive to macroeconomic conditions.

- Outlook: Despite the challenges, the US refractive market holds significant potential. The market size remains underdeveloped relative to historical highs, with 700,000-800,000 annual procedures, far below its peak. ZEISS’s technology, particularly the minimally invasive SMILE therapy, is well-positioned to capitalize on market recovery as economic conditions improve and consumer confidence returns.

What’s your outlook for US equipment sales recovery after Q3 order trends?

Stabilization: US equipment sales began stabilizing in Q3 FY24, with improving order entries and a book-to-bill ratio above 1 in the months preceding fiscal year-end. Early trends in FY25 continue to show positive momentum.

Growth Drivers: ZEISS is optimistic about growth in FY25, driven by the anticipated FDA approval of the VisuMax 800 platform in mid-2025. The new platform is expected to attract significant demand from clinics aiming to upgrade their technology and enhance patient offerings.

What feedback are you getting on the ZEISS cataract workflow?

- Market Reception: The ZEISS cataract workflow continues to be well-received, offering a comprehensive and integrated solution for cataract treatment. Feedback highlights the value of combining diagnostic imaging, surgical planning, and premium IOLs (intraocular lenses) within a single platform.

Conclusion

Sebastian Frericks highlights Carl Zeiss Meditec AG’s resilience amidst market challenges, emphasizing the company’s strategic initiatives and leadership in innovation. With advanced products like the VisuMax 800 and comprehensive cataract workflows, ZEISS is well-positioned for recovery and long-term growth in the US market.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

AIXTRON SE Elevator Pitch: Key Takeaways

Introduction to AIXTRON by Christian Ludwig, Head of Investor Relations and Corporate Communications

Christian Ludwig, Head of Investor Relations and Corporate Communications at AIXTRON, delivers a concise yet powerful elevator pitch, highlighting the company’s impressive 40-year journey. AIXTRON has established itself as a trusted global technology leader in deposition systems, addressing transformative industries with cutting-edge solutions and a strong legacy of innovation.

Corporate Overview

- Founded: 1983, as a university spin-off from RWTH Aachen.

- Global Reach: Over 1,100 employees across nine countries, with R&D and production facilities in Germany, the UK, and Italy.

- Technology Leadership: More than 3,500 deposition systems sold worldwide, with a proven track record in Power Electronics, Optoelectronics, and Laser applications.

Key Growth Applications

AIXTRON’s product portfolio is tailored for four primary growth applications:

Power Electronics

- Silicon Carbide (SiC): Revolutionizing EV main inverters, chargers, and wind power systems.

- Gallium Nitride (GaN): Powering fast chargers, motor drives, and AI power delivery solutions.

Optoelectronics

-LED Systems: Enabling next-gen industrial displays, automotive lighting, and horticulture.

-Micro LEDs and Specialty LEDs: Transforming AR glasses, TVs, and automotive interiors.

Laser Technology

- Applications in 3D Sensing, LiDAR, and Optical Data Communication.

Growth Outlook

- Recent Growth: Robust revenue growth driven by SiC and GaN applications.

- 2025 Transition: A flat-to-slight revenue decline is expected due to market adjustments.

- Long-Term Potential: Market demand is forecasted to double by 2028/29, driven by electrification, AI, IoT, and sustainable energy trends.

Strategic Achievements and Execution

- Portfolio Evolution: Continuous upgrades with the G10 product family ensure market competitiveness.

- Market Expansion: Successfully entered the SiC market while maintaining strong shares in GaN and Optoelectronics.

- ESG Alignment: High alignment with EU Taxonomy regulations demonstrates a commitment to sustainability.

Key Megatrends and Market Drivers

- Electrification and energy efficiency.

- AI, digitization, and communication technologies.

- Internet of Things (IoT) and intelligent devices.

- Transition to advanced materials in power and display applications.

Investor Appeal

Christian Ludwig concludes by emphasizing AIXTRON’s ability to outpace market growth through superior technology and alignment with structural megatrends. He invites investors to explore the company’s unique equity story, driven by long-term profitability and sustainability.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

===============================

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.